RESEARCH USE ONLY. Reference data for laboratory research. Not medical advice; not for human consumption.
Peptijournal

Compare compounds

Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.

PopularRetatrutide vs TirzepatideSemaglutide vs TirzepatideSemaglutide vs RetatrutideBPC-157 vs TB-500BPC-157 vs GHK-CuSermorelin vs Tesamorelin
AOD-9604Tesamorelin
Same goal
Include when printing

Only affects the printed page / PDF. The research-use-only notice always prints.

Protocol01
AOD-9604

Metabolic / Weight

Vials · 2 / 5 mg

Protocol02
Tesamorelin

Growth Hormone

Vials · 10 / 20 mg

01Protocol

AOD-9604

Vials
2 / 5 mg
Dosing data
Lab reference — not listed

Tesamorelin

Vials
10 / 20 mg
Dosing data
Lab reference — not listed

02Quick calculator

AOD-9604

Draw (100u)

—

Concentration

—

mg/mL

Tesamorelin

Draw (100u)

—

Concentration

—

mg/mL

03Mechanism of action

AOD-9604

AOD-9604 is a modified fragment of the C-terminal region of human growth hormone, developed to study fat metabolism without growth hormone's growth-promoting effects.

Tesamorelin

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH 1-44) with an N-terminal trans-3-hexenoyl modification that improves stability against dipeptidyl peptidase-4 cleavage. It binds GHRH receptors on anterior pituitary somatotrophs, activating Gs/cAMP signaling to stimulate pulsatile endogenous growth hormone release, which in turn raises circulating IGF-1.

04Study endpoints

AOD-9604

  • It was developed by Metabolic Pharmaceuticals as a potential obesity treatment and had reached phase IIa trials by February 2002.
  • A 2026 sports-medicine review groups it with unapproved peptides that look favourable in animal models but have scarce rigorous human safety data.

Tesamorelin

  • Reduced visceral adipose tissue (VAT) measured by CT in phase 3 trials in HIV-infected adults with abdominal fat accumulation.
  • Increased IGF-1 levels while largely preserving physiological pulsatile GH secretion.
  • Reduced hepatic fat fraction in HIV-associated fatty liver studies.
  • VAT reductions were not maintained after treatment discontinuation in trial extension phases.

05Safety & regulatory findings

AOD-9604

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • Listed as prohibited in sport by the World Anti-Doping Agency.
  • Reviewers warn of potential for serious harm when unapproved peptides are used outside regulatory oversight.

Tesamorelin

  • FDA-approved in 2010 (Egrifta) specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy.
  • Label notes that long-term cardiovascular benefit and safety have not been established, and it is not indicated for weight loss.
  • The cited approval does not establish efficacy outside its indication or approve research-market vials.

06Citations

AOD-9604

2 references · view

Tesamorelin

4 references · view